LigaTrap Technologies

Founded with a mission to revolutionize immunoglobulin purification, LigaTrap Technologies offers a patented portfolio of affinity ligands designed for the efficient purification of monoclonal and polyclonal immunoglobulins from various species. Their products, including species-specific ligands and purification resins for IgM and IgG, provide significant advantages such as milder elution conditions at pH 4.0 compared to traditional methods. LigaTrap focuses on delivering high-quality solutions to researchers and biopharmaceutical companies, enhancing the efficiency and effectiveness of antibody purification processes.

Notable figures associated with LigaTrap include its team of experienced scientists and industry experts who have contributed to the development of their innovative technologies. The company has secured investments from key stakeholders in the biotech industry, further validating its potential. LigaTrap's achievements include the successful commercialization of their proprietary ligands and resins, which have garnered positive feedback for their performance and reliability. Overall, LigaTrap Technologies is making a significant impact in the field of immunoglobulin purification, offering cutting-edge solutions that advance scientific research and biopharmaceutical manufacturing.